# Catherine Lubetzki

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/catherine-lubetzki/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,782 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 70 |
| i10-index | 179 |
| Last Known Institution | Centre National de la Recherche Scientifique |
| OpenAlex ID | https://openalex.org/A5054561765 |
| ORCID iD | 0000-0001-7164-3175 |
| Works | 352 |

## Researcher papers

Showing 12 of 14.

- [Defining the clinical course of multiple sclerosis](https://scholariq.org/papers/defining-the-clinical-course-of-multiple-sclerosis/)
- [Autoantibodies against type I IFNs in patients with life-threatening COVID-19](https://scholariq.org/papers/autoantibodies-against-type-i-ifns-in-patients-with-life-threatening-covid-19/)
- [Inborn errors of type I IFN immunity in patients with life-threatening COVID-19](https://scholariq.org/papers/inborn-errors-of-type-i-ifn-immunity-in-patients-with-life-threatening-covid-19/)
- [ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis](https://scholariq.org/papers/ectrims-ean-guideline-on-the-pharmacological-treatment-of-people-with-multiple/)
- [Induction of myelination in the central nervous system by electrical activity.](https://scholariq.org/papers/induction-of-myelination-in-the-central-nervous-system-by-electrical-activity/)
- [Natural History of Multiple Sclerosis with Childhood Onset](https://scholariq.org/papers/natural-history-of-multiple-sclerosis-with-childhood-onset/)
- [Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-glatiramer-acetate-on-conversion-to-clinically-definite-multiple/)
- [Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines](https://scholariq.org/papers/assessment-of-lesions-on-magnetic-resonance-imaging-in-multiple-sclerosis/)
- [Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis](https://scholariq.org/papers/clinical-characteristics-and-outcomes-in-patients-with-coronavirus-disease-2019/)
- [Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/oral-fingolimod-in-primary-progressive-multiple-sclerosis-informs-a-phase-3/)
- [Dynamic <scp>I</scp>maging of <scp>I</scp>ndividual <scp>R</scp>emyelination <scp>P</scp>rofiles in <scp>M</scp>ultiple <scp>S</scp>clerosis](https://scholariq.org/papers/dynamic-scp-i-scp-maging-of-scp-i-scp-ndividual-scp-r-scp-emyelination-scp-p-scp/)
- [Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers](https://scholariq.org/papers/rapid-decline-of-neutralizing-antibodies-against-sars-cov-2-among-infected/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Neurogenesis and neuroplasticity mechanisms](https://scholariq.org/topics/neurogenesis-and-neuroplasticity-mechanisms/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Nerve injury and regeneration](https://scholariq.org/topics/nerve-injury-and-regeneration/)
- [Neuroinflammation and Neurodegeneration Mechanisms](https://scholariq.org/topics/neuroinflammation-and-neurodegeneration-mechanisms/)

## Researcher university

- [Centre National de la Recherche Scientifique](https://scholariq.org/institutions/centre-national-de-la-recherche-scientifique/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.